Abstract
Real-world data inform the outcome comparisons and help the development of new therapeutic strategies. To this end, we aimed to describe the full characteristics and outcomes in the Epidemiological Strategy and Medical Economics (ESME) cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC). Women aged ≥18 years with newly diagnosed MBC and who initiated MBC treatment between January 2008 and December 2016 in one of the 18 French Comprehensive Cancer Centers (N = 22,109) were included. We assessed the full patients' characteristics, first-line treatments, overall survival (OS) and first-line progression-free survival, as well as updated prognostic factors in the whole cohort and among the 3 major subtypes: hormone receptor positive and HER2-negative (HR+/HER2-, n = 13,656), HER2-positive (HER2+, n = 4017) and triple-negative (n = 2963) tumours. The median OS of the whole cohort was 39.5 months (95% confidence interval [CI], 38.7-40.3). Five-year OS was 33.8%. OS differed significantly between the 3 subtypes (p < 0.0001) with a median OS of 43.3 (95% CI, 42.5-44.5) in HR+/HER2-; 50.1 (95% CI, 47.6-53.1) in HER2+; and 14.8 months (95% CI, 14.1-15.5) in triple-negative subgroups...Continue Reading
Citations
May 14, 2020·The Breast Journal·Aziza NassarMamatha Chivukula
Dec 12, 2020·The Breast : Official Journal of the European Society of Mastology·Khalil SalehElise Deluche
Aug 18, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Matthieu FrascaSimone Mathoulin-Pelissier
Oct 7, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elise DelucheSuzette Delaloge
Oct 8, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michael K Fink
Feb 25, 2021·Expert Opinion on Pharmacotherapy·Fanny LeenhardtWilliam Jacot
Mar 5, 2021·Breast Cancer : Targets and Therapy·Anna S LinehanPatrick G Morris
Mar 17, 2021·Genome Medicine·Céline CallensPaul Cottu
Mar 5, 2021·European Journal of Clinical Investigation·Elisa AgostinettoEvandro de Azambuja
Mar 30, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter A FaschingFergus J Couch
Apr 18, 2021·NPJ Breast Cancer·Thomas GrindaMagali Lacroix-Triki
Apr 26, 2021·ESMO Open·T GrindaS Delaloge
May 14, 2021·ESMO Open·M CarausuL Cabel
May 28, 2021·JCO Clinical Cancer Informatics·Jennifer L Caswell-JinAllison W Kurian
May 20, 2021·International Journal of General Medicine·Yi LiBiyun Wang
Jul 23, 2021·Therapeutic Advances in Medical Oncology·Yannan ZhaoBiyun Wang
Jul 26, 2021·ESMO Open·D DanoA Gonçalves
Jul 6, 2021·ESMO Open·E AdamsK Punie
Aug 31, 2021·International Journal of Cancer. Journal International Du Cancer·Marissa MeegdesVivianne C G Tjan-Heijnen
Oct 7, 2021·Scientific Reports·Maria Escala-GarciaMarjanka K Schmidt